SCHEMBL4923741

SCHEMBL4923741

Cc1cccc(C)c1Nc1ncnc2c1cnn2-c1ccc(N2CC[C@@H](N(C)C)C2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 13/20 0.52
MAPT P10636 7/20 0.52
LMNA P02545 8/20 0.52
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TSHR P16473 2/20 0.51
HTT P42858 2/20 0.51
HSD17B10 Q99714 2/20 0.51
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
NFKB1 P19838 1/20 0.45
MAPK1 P28482 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
THRB P10828 1/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923750 1.00 TP53 (0.52) TP53MAPTLMNANPC1RAB9A
SCHEMBL4921937 0.91 TP53 (0.65) TP53MAPTLMNANPC1RAB9A
SCHEMBL4926381 0.91 TP53 (0.65) TP53MAPTLMNANPC1RAB9A
SCHEMBL4921954 0.91 TP53 (0.65) TP53MAPTLMNANPC1RAB9A
SCHEMBL4915399 0.90 LMNA (0.50) TP53MAPTLMNANPC1RAB9A
SCHEMBL4928902 0.90 LMNA (0.50) TP53MAPTLMNANPC1RAB9A
SCHEMBL4915385 0.90 LMNA (0.50) TP53MAPTLMNANPC1RAB9A
SCHEMBL4927129 0.86 TP53 (0.52) TP53MAPTLMNANPC1RAB9A
SCHEMBL4920594 0.85 TP53 (0.51) TP53MAPTLMNANPC1RAB9A
SCHEMBL4921977 0.84 MAPT (0.52) TP53MAPTLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US claimed
EP-1812441-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2007-08-01 EP claimed
WO-2006050946-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-05-18 WO claimed
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors MAP3K1, MAP4K2, MAP4K5 TP53 849/4885MAPT 1638/4885LMNA 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.